Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2659681rdf:typepubmed:Citationlld:pubmed
pubmed-article:2659681lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C1328252lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:2659681lifeskim:mentionsumls-concept:C0051218lld:lifeskim
pubmed-article:2659681pubmed:issue1lld:pubmed
pubmed-article:2659681pubmed:dateCreated1989-7-27lld:pubmed
pubmed-article:2659681pubmed:abstractTextEighteen patients received 1,250 mg of allopurinol riboside (AR) four times daily for 28 d. Nine of the patients concurrently received 500 mg probenecid (PB) four times daily. Cure was assessed clinically and parasitologically. Patients who had culture-positive and nonhealing lesions 3 mo after therapy received pentavalent antimony. Of the nine patients who received AR alone, four (44%) had clinical improvement at the end of therapy and two (22%) were culture-negative. A third patient became culture negative at 2 mo after therapy. The culture-negative patients were completely healed at 1 mo and remained so at 1 y after therapy. Of the nine patients who received AR plus PB, four had complete healing and two had clinical improvement at the end of therapy; however, all patients remained culture-positive. At 2-3 mo after therapy, six (67%) of the patients were completely healed, and of these, five (56%) were culture-negative. The drug was well-tolerated.lld:pubmed
pubmed-article:2659681pubmed:languageenglld:pubmed
pubmed-article:2659681pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2659681pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2659681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2659681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2659681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2659681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2659681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2659681pubmed:statusMEDLINElld:pubmed
pubmed-article:2659681pubmed:monthJullld:pubmed
pubmed-article:2659681pubmed:issn0022-1899lld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:PanH YHYlld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:PattishallK...lld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:MarrJ JJJlld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:NelsonD JDJlld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:JohnsonC MCMlld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:SaenzR ERElld:pubmed
pubmed-article:2659681pubmed:authorpubmed-author:RogersM DMDlld:pubmed
pubmed-article:2659681pubmed:issnTypePrintlld:pubmed
pubmed-article:2659681pubmed:volume160lld:pubmed
pubmed-article:2659681pubmed:ownerNLMlld:pubmed
pubmed-article:2659681pubmed:authorsCompleteYlld:pubmed
pubmed-article:2659681pubmed:pagination153-8lld:pubmed
pubmed-article:2659681pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:meshHeadingpubmed-meshheading:2659681-...lld:pubmed
pubmed-article:2659681pubmed:year1989lld:pubmed
pubmed-article:2659681pubmed:articleTitleTreatment of American cutaneous leishmaniasis with orally administered allopurinol riboside.lld:pubmed
pubmed-article:2659681pubmed:affiliationGorgas Memorial Laboratory, Panama City, Republic of Panama.lld:pubmed
pubmed-article:2659681pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2659681pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2659681pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2659681pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2659681lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2659681lld:pubmed